Certara heads into its third-quarter report with a stock price that has run well ahead of its income statement. Shares have climbed about 73% since the company last reported, while the S&P 500 barely moved, yet the business behind that rally is still guiding to growth of zero to 4% and absorbing stranded costs from a divestiture. That gap between enthusiasm and fundamentals is what makes this report interesting. The rally has priced in a turnaround story built on improving software momentum and a new leadership team. The upcoming numbers need to show that the story is moving from promise to proof.
The Street's quarterly bar is modest. Consensus calls for earnings of $0.06 per share on revenue of $92.2 million, which would mark a 33% decline in profit and a roughly 12% drop in sales from a year ago. Those comparisons look worse than the underlying trend, since the year-ago period appears to include the regulatory and medical-writing business Certara has since sold. Against last quarter's $93.3 million and $0.05, the estimate implies a roughly flat sequential top line with slightly better profitability. The full-year picture is muddier. The company's most recent stated outlook calls for $0.35 to $0.41 per share on $395 million to $405 million in revenue, and consensus of $0.40 on $399.6 million sits near the upper half of that range. However, on the last call management framed continuing-operations guidance at $367 million to $382 million in revenue, adjusted EPS of $0.31 to $0.36, and an adjusted EBITDA margin of 29% to 31%, a step down from earlier ranges. Clarity on which basis the Street should anchor to would be useful, because full-year EPS expectations have already been trimmed twice from the $0.44 to $0.48 range offered at the start of the year.
Software is the part of the business carrying the bull case. Software bookings swung from a 6% decline late last year to gains of 20% and 9% in the first two quarters of 2026, trailing bookings excluding a large prior contract improved to 7%, and the pipeline expanded 27%. Management said software revenue should land at or above the top of its range. A third straight quarter of solid bookings growth, ideally with early traction from the NVIDIA collaboration, the next-generation AI platform, or the recent first SimSip win in China, would validate the claim that the rebound is durable rather than lumpy. A sharp bookings slowdown would raise the uncomfortable question of whether the first half simply pulled deals forward.
Services is where the narrative is most exposed. Revenue fell 3% last quarter, bookings dropped 6%, and book-to-bill was only 1.07, extending weakness among large pharmaceutical customers that first surfaced a year ago. Management has reorganized into two business units and installed a new chief commercial officer as of August 1, explicitly leaning on back-half pipeline conversion. This is the first full quarter with that structure in place, so services bookings and book-to-bill are the cleanest read on whether the overhaul is working. Margins matter too: adjusted EBITDA margin slipped to 28.1% last quarter, below the full-year guide, so the roughly $13 million in run-rate cost savings and AI-driven productivity gains need to start offsetting stranded costs.
Sentiment has warmed but remains cautious, with the bearish reading easing to about 18% from nearly 41% before the prior report. The stock trades far above its 200-day moving average near $7.25 and sits essentially at its post-earnings high of $10.98, putting it right at the edge of a breakout. That positioning cuts both ways, since a clean report could extend the move while any wobble may invite profit-taking.
The central issue is whether services stops shrinking. Software has done its part, but with a lowered margin guide, an interim CFO, and a recent reduction in force, Certara needs evidence that its commercial reset is converting pipeline into bookings for the rally's turnaround thesis to hold.